News

Lightlake is focused on developing addiction treatments based on its expertise in opioid antagonists. In December 2014, Lightlake in partnership with the National Institute on Drug Abuse (NIDA),

The company noted that the FDA approved prescription treatment option is now available in pharmacies nationwide for patients with rosacea, a common, inflammatory disorder affecting the face. The

A total of 2,021 patients were enrolled in the both the randomized, double-blind, placebo-controlled, multi-centered trials at participating clinics and practices in the Americas, Europe, Australia, New Zealand

Under the deal, the two parties will collaborate on an NIH-sponsored Phase II trial of AV-101, VistaGen’s orally-active NMDA receptor modulator, in MDD patients. MDD is a debilitating

The injection is indicated for prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery, or in medical patients with severely restricted

The company is developing GLPG1690 in collaboration with Janssen Pharmaceutica. Around 40 healthy volunteers were included in the trial, which evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of

The launch of three drug discovery institutes at the University of Cambridge, University of Oxford and University College London (UCL) will see 90 new research scientists recruited over

Banzel is a triazole derivative, which is structurally unrelated to currently marketed antiepileptic drugs. Earlier, the FDA had approved Banzel as adjunctive treatment of seizures associated with LGS

Inflectra is a chimeric human murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF alpha but not to lymphotoxin a (TNF